Core Insights - UroGen Pharma Ltd. announced the publication of a comprehensive review of ZUSDURI™ (mitomycin) for intravesical solution, the first FDA-approved treatment for adults with recurrent, low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) [1][2] Company Overview - UroGen Pharma is focused on developing innovative solutions for urothelial and specialty cancers, utilizing proprietary RTGel technology for sustained release of medications [11] - The company is headquartered in Princeton, NJ, with operations in Israel [11] Product Information - ZUSDURI is a non-surgical treatment option that has shown robust and durable complete response rates in clinical trials for recurrent LG-IR-NMIBC [2][3] - The drug is administered in an outpatient setting without the need for general anesthesia, making it a convenient option for patients [2] Clinical Development - The clinical development program for ZUSDURI includes three late-phase trials: OPTIMA II, ATLAS, and ENVISION, which evaluated its safety and efficacy [3][6] - The ENVISION trial enrolled 240 patients and assessed the complete response rate at three months post-treatment [8] Efficacy and Safety - Complete response rates in late-stage trials ranged from 64.8% to 79.6% at three months, with 80.6% of patients remaining disease-free at 18 months following complete response [6] - Adverse events were primarily localized to the lower urinary tract, with serious adverse reactions occurring in 12% of patients [6] Patient Demographics - Patients in the ZUSDURI clinical trials were predominantly elderly, with median ages between 67 and 70 years, and a significant proportion had multiple tumors and larger tumor sizes [4] Market Context - LG-IR-NMIBC affects approximately 82,000 individuals annually in the U.S., with around 59,000 being recurrent cases [7] - The standard care for NMIBC typically involves transurethral resection of bladder tumor (TURBT), but many patients experience recurrences [7]

Core Insights - UroGen Pharma Ltd. announced the publication of a five-year long-term extension study of the Phase 2b OPTIMA II trial, demonstrating durable long-term complete responses in patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) treated with ZUSDURI (mitomycin) [1][2] Company Overview - UroGen Pharma is a biotech company focused on developing innovative solutions for urothelial and specialty cancers, utilizing proprietary RTGel technology for sustained drug release [10] - ZUSDURI is specifically indicated for the treatment of adults with recurrent LG-IR-NMIBC, providing a non-surgical treatment option [5][11] Clinical Study Findings - The OPTIMA II trial included both newly diagnosed and recurrent adult patients with LG-IR-NMIBC, with 41 patients achieving complete response (CR) at three months post-treatment; 25 remained in CR at 12 months [2][4] - Among the 17 patients who entered the long-term follow-up study, the median duration of response (DOR) was 42.1 months, indicating ZUSDURI's potential for meaningful, lasting event-free periods [2][7] - The median Kaplan-Meier estimate of DOR for all 41 patients was 24.2 months, with a median follow-up of 35.8 months [2] Patient Demographics - The study cohort consisted of 17 patients, of which 16 (94%) were recurrent cases, highlighting the drug's relevance for patients facing repeated surgeries [4] Treatment Efficacy - ZUSDURI's long-term data emphasizes its ability to deliver sustained responses in an outpatient setting, which is particularly valuable for recurrent patients [2][3] - The study results reflect a commitment to providing innovative treatments that empower patients and physicians with more options [3] Safety Profile - Safety data were not collected during the long-term follow-up trial; however, the most commonly reported treatment-emergent adverse events in the parent OPTIMA II study included dysuria (41%), pollakiuria (21%), and hematuria (16%) [3][4]